BARRY KALLANDER is an experienced executive who has held positions as CEO, Chairman, senior vice president and vice president in operations, service delivery, sales, and consulting. During his 30-year career, Mr. Kallander has lead businesses providing management consulting, strategy, software, and hardware solutions to the electric power, financial services, major manufacturing, and high tech industries. He has held senior executive positions in companies ranging from venture-backed startups to $5B conglomerates. His broad industry background coupled with his management experience allows him to spin up quickly in virtually any situation.

MARK CARBEAU is a transformative healthcare leader who brings to Interleukin Genetics more than three decades of business expertise in the life science industries, with a proven track record of building high growth diagnostic and pharmaceutical businesses. He began his career with Eli Lilly and Company. He founded CM Partners, a strategic life science consulting firm, and was a member of The Boston Consulting Group. He served as Vice President of Corporate Development at OraPharma during its commercial launch of a periodontal therapeutic, a successful IPO, and the eventual sale of the company to Johnson & Johnson. He also served as President USA of Kinetic Concepts, President and CEO of HyperMed, and CEO of PolyRemedy. Prior to joining Interleukin Genetics, Mr. Carbeau was Co-Founder and CEO of Diagnostyx, a technology company focused on intelligent drug infusion systems. Mr. Carbeau holds a B.S. in Industrial Engineering from Penn State University and an MBA from the Wharton School of the University of Pennsylvania.

DAYTON MISFELDT joined the Board of Directors in May 2013. Mr. Misfeldt is an Investment Partner at Bay City Capital LLC, a leading, global life sciences investment firm, and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at LifeScience Economics. Mr. Misfeldt received a B.A. in Economics from the University of California, San Diego. Mr. Misfeldt currently serves on the Board of Directors of Sunesis Pharmaceuticals, Inc, a publicly traded biopharmaceutical company.